Corporate Integrity Agreements Offer Lessons For Voluntary Compliance Plans
Executive Summary
Manufacturer compliance programs for promotional activities should be based upon a thorough understanding of a company's personnel, sales tools, promotional money and internal monitoring capabilities, HHS Office of Inspector General Administrative & Civil Remedies Branch Senior Counsel Mary Riordan said Sept. 19
You may also be interested in...
Pfizer To Monitor Off-Label Drug Use Under Neurontin Settlement
Pfizer will provide periodic reports to the HHS Inspector General about off-label use trends for its products under the May 13 settlement of an investigation into the company's promotion of Neurontin
TAP To Audit Marketing Documents Related To Top Lupron, Prevacid Buyers
TAP Pharmaceuticals' corporate integrity agreement with the HHS Inspector General calls for annual audits of the sales and marketing documents related to transactions with the largest volume purchasers of Lupron and Prevacid.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011